Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut for all 'Designated Persons' and their 'Immediate Relatives' starting from Wednesday, July 01, 2026. It will reopen 48 hours after the announcement of the company's Unaudited Financial Results for the quarter ending June 30, 2026. The exact date for the Board Meeting to consider these financial results will be communicated later.

Shree Ganesh Remedies Ltd reported its Q4 and FY26 financial results. For the year ended March 31, 2026, the company's revenue stood at ₹109.29 Cr, a 1% increase YoY, while EBITDA decreased by 11% to ₹35.02 Cr, and PAT decreased by 23% to ₹17.77 Cr. The company is progressing on CRAMS engagements and expects commercial production from Block 7 expansion to commence in Q2FY27. The management noted FY26 as a year of consolidation, with a focus on strengthening the business foundation.

Shree Ganesh Remedies Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the re-appointment of M/s. S N D K & Associates LLP as Internal Auditors for FY 2026-27. The auditors issued unmodified opinions on the financial results.

Shree Ganesh Remedies Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditors issued unmodified audit reports. Additionally, M/s. S N D K & Associates LLP was re-appointed as Internal Auditors for FY 2026-27.

Shree Ganesh Remedies Ltd has announced a Board of Directors meeting scheduled for May 14, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The trading window for dealing in the company's shares has been closed since April 1, 2026, and will remain closed until 48 hours after the board meeting.

Shree Ganesh Remedies Ltd has announced the closure of the trading window for 'Designated Persons' and their 'Immediate Relatives' as per the SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure will be in effect from Wednesday, April 01, 2026, until 48 hours after the announcement of the Audited Financial Results for the quarter and year ended on March 31, 2026. The date of the Board Meeting for considering the Audited Financial Results and the Audit Report will be intimated later.

Shree Ganesh Remedies Limited, a fast-growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q3 & IMFY26. The company faced challenges including delays in shipments, a challenging demand environment in Europe, and heightened competitive intensity, leading to a 22% YoY decline in revenue. Despite this, the company remains focused on execution, capability-building, and driving volume improvement. The new pilot facility is now commissioned, and the expansion programme for Block 7 is progressing as planned. The CRAMS engagement with the Japanese client is also advancing positively. The company expects a gradual improvement in business momentum in FY27.

The Board of Directors of Shree Ganesh Remedies Ltd. has approved the unaudited financial results (standalone and consolidated) for the quarter and nine months ended on December 31, 2025. The company's total revenue for the quarter ended December 31, 2025, was NIL lakhs and the total net profit/ (loss) after tax was (0.95) lakhs. The meeting of the Board of Directors commenced at 2:45 p.m. and concluded at 03:35 p.m. The review report was submitted by Chaudhary Shah & Associates LLP, the independent auditor of the entity.

Shree Ganesh Remedies Ltd. has informed BSE that a meeting of the Board of Directors is scheduled on January 23, 2026, to consider and approve the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. The trading window for dealing/trading in the shares of the company by designated persons was closed from January 1, 2026, as per the Company's Code of Conduct for prohibition of insider trading and shall remain closed till 48 hours after the announcement of the Unaudited Financial Results.

Shree Ganesh Remedies Ltd has announced the re-appointment of Mr. Parth Chandulal Kothia as a Whole-time Director and Chief Financial Officer for a further period of 5 years, effective from January 17, 2026. This decision was made at the Board of Directors meeting held on January 16, 2026, based on the recommendation of the Nomination and Remuneration Committee. Mr. Kothia has been instrumental in driving the company's growth since he joined in 2021. His marketing and finance initiatives have had an organization-wide impact. Mr. Kothia is a Graduate in Chemical Engineering and holds a Master of Science degree in Global Finance from Fordham University, USA. He has more than five years of experience in Business Development for Pharmaceutical Intermediates and Specialty Chemicals. The re-appointment is subject to the approval of the Members.